

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RYAN ARTHUR F			2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/03/2022			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
777 OLD SAW MILL RIVER ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) TARRYTOWN NY 10591								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/03/2022		S ⁽¹⁾		1	D	\$621.98	22,490	D	
Common Stock	01/03/2022		S ⁽¹⁾		8	D	\$622.52 ⁽²⁾	22,482	D	
Common Stock	01/03/2022		S ⁽¹⁾		19	D	\$623.62 ⁽³⁾	22,463	D	
Common Stock	01/03/2022		S ⁽¹⁾		14	D	\$624.3 ⁽⁴⁾	22,449	D	
Common Stock	01/03/2022		S ⁽¹⁾		45	D	\$625.56 ⁽⁵⁾	22,404	D	
Common Stock	01/03/2022		S ⁽¹⁾		5	D	\$626.48 ⁽⁶⁾	22,399	D	
Common Stock	01/03/2022		S ⁽¹⁾		6	D	\$627.22 ⁽⁷⁾	22,393	D	
Common Stock	01/03/2022		S ⁽¹⁾		2	D	\$628.87 ⁽⁸⁾	22,391	D	
Common Stock	01/03/2022		A ⁽⁹⁾		191	A	\$0.0	22,582	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Non-Qualified Stock Option (right to buy)	\$625.6	01/03/2022		A		2,707		⁽¹⁰⁾	01/03/2032	Common Stock	2,707		D	

Explanation of Responses:

- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 8 shares of Company stock on January 3, 2022 at prices ranging from \$622.32 to \$622.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Represents volume-weighted average price of sales of 19 shares of Company stock on January 3, 2022 at prices ranging from \$623.41 to \$623.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Represents volume-weighted average price of sales of 14 shares of Company stock on January 3, 2022 at prices ranging from \$624.04 to \$624.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Represents volume-weighted average price of sales of 45 shares of Company stock on January 3, 2022 at prices ranging from \$625.00 to \$625.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Represents volume-weighted average price of sales of 5 shares of Company stock on January 3, 2022 at prices ranging from \$626.29 to \$626.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Represents volume-weighted average price of sales of 6 shares of Company stock on January 3, 2022 at prices ranging from \$627.00 to \$627.31. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Represents volume-weighted average price of sales of 2 shares of Company stock on January 3, 2022 at prices ranging from \$628.76 to \$628.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 3, 2022 at each separate price.
- Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Company's common stock.
- On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

/s/**Arthur F. Ryan

01/05/2022

** Signature of Reporting Person

Date

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.